MHM Magazine

References: 1. Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J, for 316 Study Group. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010; 6 :34. Available from: http://www.behavioralandbrainfunctions. com/content/6/1/34 [Accessed 18th August 2021]. 2. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amfetamine. Neuropsychiatr Dis Treat. 2010; 6 :317-327. 3. Frampton JE. Lisdexamfetamine: A Review in ADHD in Adults. CNS Drugs 2016: 30 (4):343-54.DOI 10.1007/s40263-016-0327-6. 4. Adler LA, Dirks B, Deas PF, Raychaudhuri A, Dauphin MR, Lasser RA, et al. Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/ Hyperactivity Disorder Who Report Clinically Significant Impairment in Executive Function: Results From a Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2013; 74 (7):694-702. 5. VYVANSE ® 30,50,70. SAHPRA approved professional information. Takeda (Pty) Ltd. 24 July, 2020. 6. Coghill DR, Caballero B, Sorooshian S, Civil R. A Systematic Review of the Safety of Lisdexamfetamine Dimesylate. CNS Drugs 2014; 28 :497–511. S6 VYVANSE ® 30 . Each capsule contains 30 mg lisdexamfetamine dimesilate. Reg. No: 48/1.6/0407. S6 VYVANSE ® 50 . Each capsule contains 50 mg lisdexamfetamine dimesilate. Reg. No: 48/1.6/0408. S6 VYVANSE ® 70 . Each capsule contains 70 mg lisdexamfetamine dimesilate. Reg. No: 48/1.6/0409. For full prescribing information, refer to the Vyvanse Professional Information as approved by SAHPRA. Takeda (Pty) Ltd, Reg. No.: 1982/011215/07, Building A, Monte Circle, 64 Montecasino Boulevard, Fourways 2191. Tel: +27115143000. Marketed by Acino Pharma (Pty) Ltd. Reg. No: 1994/008717/07. No 106, 16th Road, Midrand, 1686, Gauteng, South Africa. (011) 516-1700. www.acino.co.za C-APROM/ZA/Vyv/0040. VYVANSE ® offers sustained improvement in adult attention deficit hyperactivity disorder (ADHD) symptoms for up to 14 hours 1 NO ONE SEES THEIR ADHD BUT EVERYONE SEES THEIR SUCCESS NO ONE SEES THEIR ADHD BUT EVERYONE SEES THEIR POTENTIAL VYVANSE ® is the FIRST prodrug stimulant 2,3 Offers improvement in real-life executive function deficits and self-reported quality of life 3,4 Convenient once-daily dosing with a well-established safety profile 3,5,6